Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bintrafusp Alfa and Radiation in Advanced Intrahepatic Cholangiocarcinoma
NCT04708067Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2021
- Primary completion
- Feb 2027
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bintrafusp alfa in intrahepatic cholangiocarcinoma (ICC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of adverse events at 60 days. Started Aug 2021; status: active, not recruiting.
02
Drugs
bintrafusp alfa
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT04708067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04708067.